Sara Nayeem joined NEA's healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana, Cydan and Vtesse and as a board observer for Loxo Oncology (LOXO), Zyngenia, and Ziarco. She previously served as a board observer for Epizyme (EPZM), Tesaro (TSRO), and Omthera (acquired by AstraZeneca).
She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, and Edimer and assists with the management of several of NEA's publicly traded portfolio companies. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions.
Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration.
Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.
Fund's investment verticals: communications, software, electronics, healthcare, energy and information technology.